Tirzepatideisthemostusefulpeptideforresearchin2024even2025!
-ByPhcokerTirzepatidepeptideisaglucose-dependentinsulinotropicpolypeptide(GIP)receptorand glucagon-likepeptide-1(GLP-1)dualreceptoragonistThedrugiscurrentlyapprovedby theFDAunderthebrandnameofMounjaroforthetreatmentoftype2diabetesAccording Tirzepatideresearchresult,thecurrentclinicaltrialresultsshowthattheparticipantsinthe experimentshowedasubstantialweightlossParticipantswhousedthehighestdoseof 15mglostanaverageof15.7%oftheirweight,whichisamajormilestoneinthehistoryof weightlossdrugs
1.LatestresearchonTirzepatide:Tirzepatidemayrelieveobstructivesleepapne a
EliLillyandCompanyannouncedthelateststudyofTirzepatidepowderonApril17,2024:Accordingto theresultsoftwoPhase3trials,foradultswithmoderateorsevereobstructivesleepapneaandobesity, Tirzepatideoneyearaftertaking10mgor15mg,theseverityofsleepapneasymptomsdecreased Patientsexperiencedamedianreductioninapnea-hypopneaindex(API)ofupto63%afterinjection
Obstructivesleepapneacausesadecreaseinbloodoxygensaturation,whichcanleadtoserious complications,includinghighbloodpressure,heartdisease,stroke,heartfailure,atrialfibrillation,and type2diabetes.Thisindex,whichmeasuresthenumberoftimesperhouraperson'sbreathsshow limitedorcompleteobstructionofairflow,istheprimarytoolforassessingtheseverityofOSAandthe effectivenessoftreatment
TheSURMOUNT-OSAStudy1evaluatedtheeffectivenessofTirzepatideinpatientsnotusingaCPAP machine.TheLillydrugwasassociatedwithameanreductionfrombaselineof27.4eventsperhour, comparedto48forplaceboInaddition,theresearchersalsosaidthatTirzepatidewasabletoreduce bodyweightbyanaverageof18.1%,comparedwith1.3%forplacebo.
PatientsreceivingCPAPintheSURMOUNT-OSAStudy2experiencedanaverageof304fewerevents perhourcomparedwith60fewereventsperhourforplaceboMeanwhile,averageweightlossin Tirzepatidewas201%,comparedwith23%inplacebo
JeffEmmick,MD,said:"Withmorethan20millionpeoplesufferingfromsevereOSA,and85%ofOSA casesgoingundiagnosed,itisimportanttoaddressthisneedhead-on.Althoughtherearemedications totreatexcessivesleepinessassociatedwithOSA,Tirzepatidehasthepotentialtobecomeatarget" Thefirstmedicaltreatmentfortheunderlyingdisease.
ThislatestresearchonTirzepatidepeptideprovidesanewresearchdirectionforOSAtreatment.Ifyou areinterestedinthisstudy,makesureyoupurchaseTirzepatide10mgor15mgfromareliable Tirzepatidesupplier
2.TirzepatideVsSemaglutide
TirzepatideandSemaglutidearetwodrugscurrentlyonthemarketforweightmanagementand treatmentoftype2diabetes.[9]Itisbecomingmoreandmorecommontousedrugstoloseweight,so whatarethesimilaritiesanddifferencesbetweenTirzepatideandSemaglutide?Herelet’shavea detailedview TirzepatideandSemaglutidebothbelongtotheGLP-1seriesofweightlossdrugsandhaveahuge effectonweightlossandthetreatmentandmanagementoftype2diabetesAndthesideeffectscaused byusingthesetwodrugsaregenerallythesameThemainsideeffectisadverseintestinalreactions
IsTirzepatidebetterthanSemaglutide?
Semaglutideisaglucagon-likepeptide(GLP-1)receptoragonist.Wheneating,itpromotestherelease ofGLP-1hormoneandproducesinsulinAtthesametime,itcanalsosendsatietysignalstothebrain, therebyreducingfoodintakeandachievingweightloss.
Tirzepatideisanagonistoftworeceptors:glucagon-likepeptide(GLP-1)andglucose-dependent insulinotropicpolypeptide(GIP),whichmeansthatTirzepatidemayalsoprovideadditionaleffectson weightlossandachievebetterresultsTheamountofweightlosseffect
Cantheyallpromoteweightloss?
Asthestudycontinued,researchersfoundthatTirzepatideledtogreaterweightlossthanSemaglutide TheresearchonTirzepatideandSemaglutidehaveshownsignificantweightlosswithweeklydosesof5 mg,10mgand15mgofTirzepatideAlthoughTirzepatidecostismoreexpensivethanSemaglutide,itis moreeffectiveandbettervalue
Ofnote,thedosesofTirzepatideandSemaglutideusedinthesestudiesweredifferentThedosageof Tirzepatideintheseexperimentswashigher,whichmayhavehadacertainimpactontheresultsofthe experimentsInaddition,thesestudiesonlycomparedpatientswithtype2diabetes,andtheeffectsof weightlossonobesepatientswithouttype2diabeteshavenotbeenclearlycompared 3.PolypeptideWeightLossDrugVsTraditionalWeightLossDrug
Famouspolypeptideweightlossdrug
Tirzepatide:isasyntheticderivativeofpolypeptidethatcombinesthefunctionsofgastricinhibitory polypeptide(GIP)andglucagon-likepeptide-1(GLP-1)Mayreduceappetiteandpromoteweightlossby slowinggastricemptyingandpromotingafeelingoffullness
Semaglutide:isasyntheticderivativeofpolypeptidebasedonthenaturallyoccurringGLP-1peptide.It promotesweightlossbysuppressingappetite,prolongingthetimeittakesfoodtopassthroughthe stomach,causingafeelingoffullness,andreducingcalorieintake
Retatrutide:isanewlylaunchedpolypeptideweightlossproductItcansuppressappetite,reduce calorieintake,therebypreventingfataccumulationandincreasingenergyexpenditure,soastoachieve thepurposeofweightloss
Famoustraditionalweightlossdrug
Sibutramine:Introducedin1997,itislicensedworldwidefordailyuseindosesof10to15mg Sibutraminhasbeenshowntopromotemodestweightloss,butconcernsaboutadversecardiovascular effectshavelimiteditsmarketpenetration
Lorcaserin:reducesappetitebyactivatingatypeofserotoninreceptorcalledthe5-HT2Creceptorinan areaofthebraincalledthehypothalamus,whichcontrolsappetiteItwasremovedfromtheUSmarket in2020becauseofanincreasedriskofcancerdetectedinusers
Rimonabant:Rimonabantisaselectivecannabinoid1receptorblockerthatreducesappetite,thereby promotingweightlossTheproductwaspulledbecauseofreportsofseriouspsychiatricsideeffects, includinganxietyanddepression
Comparingthetwo,whoisbetter?
Ofcourse,polypeptideweightlossdrugsarebetter.
①Intermsofefficacy,sometraditionalweightlossproductshavelittleeffectonweightloss(like Rimonabant),andsomestopusingthemwillleadtoweightrebound(likeSibutramine).Theweightloss effectofpolypeptideweightlossproductsisremarkable,anditsweightlosseffectcanusuallyreach 10%-20%,andtherewillbebasicallynoweightreboundafterstoppinguse
②Intermsofsideeffects,thesideeffectsoftraditionalweightlossproductsarerelativelyserious, whichcanpotentiallyleadtosideeffectssuchascancer,cardiovasculardisease,andneurological damage.Peptideweightlossproducts,asbiologicaldrugs,haverelativelysmallsideeffects.Different fromtraditionalweightlossproducts,thiskindofproductwillnotcausetheabove-mentioneddiseases, anditcaneventreattheabove-mentioneddiseasessynergistically,whichcanbesaidtokilltwobirds withonestone
③Intermsofthewayofadministration,mostofthetraditionalweight-lossdrugsaretakenorally Beforethefinaldigestionandabsorption,thedrugconsumesalot,resultinginpoorfinaleffect,andmost ofthemneedtobetakeneveryday,whichisthree-pointpoisonoustopeopleItisnotveryconvenient fordailygrocery.Peptideweightlossdrugscaneffectivelyreduceconsumptionandachievebetter
resultsthroughinjectionAtthesametime,mostpeptideweight-lossdrugsareregisteredonceaweek, whichcangreatlyprovideconvenienceforusers
Therefore,multiplecomparisonsshowthatpolypeptideweightlossproductsarebetter
4.HowToReconstituteTirzepatidePowder?
DuetothesurgeindemandforTirzepatideinthemarket,theproductionandsupplypressureof TirzepatidecontinuestoincreaseThereforemanypeopleturntobuyTirzepatidepowderonline forrestructuring.ItisimportanttobuyTirzepatidepowderfromtheregularpeptidemanufacturers. Manypeptidecompanies,scientificresearchinstitutionsetcprovidetirzepatidepowder,toensur ethequality,thetirzepatidesuppliermusthaveastrictproductionenvironment,professionaltech nologyandequipment,andbeabletoprovidecorrespondingprofessionaltestreportssuchasC oa,HPLCetcPhcokerisoneofthetopTirzepatidepowdermanufacturersinthemarketHerel et’shavealookatthereconstituteprocessofTirzepatidepowderstepbystep.
Step1:Restructuretheenvironment
WhenyoureconstructTirzepatide,youneedtofindacleanandwell-litspacetoensurethatTirz epatidedoesnotbecomecontaminated.
Step2:Preparationbeforerefactoring
Youneedtopreparethingsyoumayneedforreconstitution,suchasTirzepatidepowder,bacteri ostaticwater,syringes,vialadapters,etc
Step3:Washyourhands
Beforerefactoring,youneedtowashyourhandsthoroughlywithsoaporhandsanitizerandrun ningwatertoavoidtheintroductionofbacteriaorothercontaminants
Step4:ReconstituteTirzepatidePowder
PleasefollowthestepsbelowtocarryoutthereconstitutionprocessofTirzepatidepowder:
CheckwhethertheTirzepatidevialisdamagedorcontaminatedDonotuseitifthereisanydis colorationofthepowderasmentionedabove
Removetheprotectivecoverofthevialanddisinfectitwithalcoholcotton
Injectbacteriostaticwater
GentlyrotatethevialtofullyblendtheTirzepatidepowderandbacteriostaticwater
Checkwhetherthereareparticlesoragglomeratesinthesolutiontoensurecompletedissolution
Step5:Takeoutthesolution
InvertthevialanddrawouttherequireddoseofTirzepatidesolutionAndcheckwhetherthere areairbubblesinthesyringeIfthereareairbubbles,tapthesyringetoremovetheairbubble s.
Step6:Administration
AdministertheTirzepatidesolutioninthesyringeatthecorrectinjectionsiteasdirected
YoucanfindmanyinstructionalvideosforhomemadeinjectionsonsocialplatformssuchasTikT okandYouTube.Theaboveoperationmethodsareforreferenceonly.TheTirzepatidelyophilize dpowderusedcomesfromtheprofessionalpeptidemanufacturerPhcokercom
5.HowToStoreTirzepatidePeptide?
Normaltemperature(nothigherthan30℃)
Tirzepatidecanbestoredatroomtemperatureforupto21daysPleaseensurethatthetemper aturedoesnotexceed30°Candavoidexposuretolight
Refrigerated(2℃-8℃)
ItshouldbenotedthatthetemperatureofTirzepatideneedstobekeptbetween2-8°Cwhenref rigerated.Itcannotbefrozenandstored,asthiswilldecomposethemedicinalpropertiesofTirz epatide
PleasetakegoodcareofyourTirzepatidesothatitcanachievethedesiredresults
ReferencedCitations：
[1]"Australianprescriptionmedicinedecisionsummaries:Mounjaro"TherapeuticGoodsAdministration Archivedfromtheoriginalon5February2023Retrieved28February2023
[2]"Mounjarotirzepatide15mg/05mLsolutionforinjectionpre-filledpen(379334)"TherapeuticGoods Administration.Archivedfromtheoriginalon3January2023.Retrieved28February2023.
[3]"PublicSummary:Mounjarotirzepatide15mg/05mLsolutionforinjectionpre-filledpen"Therapeutic GoodsAdministration.Retrieved28February2023
[4]"Notice:MultipleAdditionstothePrescriptionDrugList(PDL)[2023-03-08]"HealthCanada8March 2023.Archivedfromtheoriginalon22March2023.Retrieved21March2023.
[5]"SummaryBasisofDecision-Mounjaro"HealthCanada17March2023Archivedfromtheoriginal on25April2023Retrieved24April2023
[6]ThomasMK,NikooienejadA,BrayR,CuiX,WilsonJ,DuffinK,etal(January2021)"DualGIPand GLP-1ReceptorAgonistTirzepatideImprovesBeta-cellFunctionandInsulinSensitivityinType2 Diabetes".TheJournalofClinicalEndocrinologyandMetabolism.106(2):388–396. doi:101210/clinem/dgaa863PMC7823251PMID33236115
[7]"FDAApprovesNovel,Dual-TargetedTreatmentforType2Diabetes".U.S.FoodandDrug Administration(FDA)(Pressrelease)13May2022Archivedfromtheoriginalon13May2022 Retrieved13May2022PublicDomainThisarticleincorporatestextfromthissource,whichisinthe publicdomain.
[8]NewDrugTherapyApprovals2022(PDF)USFoodandDrugAdministration(FDA)(Report) January2024.Archivedfromtheoriginalon14January2024.Retrieved14January2024.Public DomainThisarticleincorporatestextfromthissource,whichisinthepublicdomain
[9]MinT,BainSC(January2021)."TheRoleofTirzepatide,DualGIPandGLP-1ReceptorAgonist,in theManagementofType2Diabetes:TheSURPASSClinicalTrials"DiabetesTherapy12(1):143–157 doi:101007/s13300-020-00981-0PMC7843845PMID33325008
[10]KolataG(8November2023)"FDAApprovesNewObesityDrugTirzepatideThatWillCompete WithWegovy"TheNewYorkTimesArchivedfromtheoriginalon9November2023Retrieved9 November2023
[11]FriasJP,NauckMA,VanJ,BensonC,BrayR,CuiX,etal(June2020)"Efficacyandtolerabilityof tirzepatide,adualglucose-dependentinsulinotropicpeptideandglucagon-likepeptide-1receptor agonistinpatientswithtype2diabetes:A12-week,randomized,double-blind,placebo-controlledstudy toevaluatedifferentdos".Diabetes,Obesity&Metabolism.22(6):938–946.doi:10.1111/dom.13979. PMC7318331PMID31984598
[12]DahlD,OnishiY,NorwoodP,HuhR,BrayR,PatelH,etal(February2022)"Effectof SubcutaneousTirzepatidevsPlaceboAddedtoTitratedInsulinGlargineonGlycemicControlinPatients WithType2Diabetes:TheSURPASS-5RandomizedClinicalTrial"JAMA327(6):534–545 doi:10.1001/jama.2022.0078.PMC8826179.PMID35133415
[13]FriasJP,NauckMA,VanJ,KutnerME,CuiX,BensonC,etal(November2018)"Efficacyand safetyofLY3298176,anoveldualGIPandGLP-1receptoragonist,inpatientswithtype2diabetes:a randomised,placebo-controlledandactivecomparator-controlledphase2trial"TheLancet392 (10160):2180–2193doi:101016/S0140-6736(18)32260-8PMID30293770
[14]WillardFS,DourosJD,GabeMB,ShowalterAD,WainscottDB,SuterTM,etal(September2020) "TirzepatideisanimbalancedandbiaseddualGIPandGLP-1receptoragonist"JCIInsight5(17) doi:10.1172/jci.insight.140532.PMC7526454.PMID32730231
[15]ØstergaardS,PaulssonJF,KofoedJ,ZoselF,OlsenJ,JeppesenCB,etal(October2021)"The effectoffattydiacidacylationofhumanPYY3-36onY2receptorpotencyandhalf-lifeinminipigs". ScientificReports11(1):21179Bibcode:2021NatSR1121179Odoi:101038/s41598-021-00654-3 PMC8551270PMID34707178
Authorofthisarticle:
DrJeanZenggraduatedfromking’scollegelondonFacultyofLifeSciences&Medicine
ScientificJournalpaperAuthor:
1GiovanniPacini
IndependentResearcher,Padova,Italy
2KazuhikoKido
PharmD,BCCP,BCPS,ClinicalAssociateProfessor,DepartmentofClinicalPharmacy,WestVirginia UniversitySchoolofPharmacy
3JessicaWSkelley
PharmD,BCACP,Professor,DepartmentofPharmacyPractice,McWhorterSchoolofPharmacy, SamfordUniversity,Birmingham,AL
4QiLiu
DepartmentofCardiology,RenminHospitalofWuhanUniversity,Wuhan430060,Hubei,PRChina
5.StephenJ.NichollsMBBS,PhD
VictorianHeartInstitute,MonashUniversity,VIC,Melbourne,Australia